ConductScience.org, home

Comparison · NCT00645099-95140d01

Paliperidone ER vs Olanzapine: Number of Patients Meeting the Criteria for Type 2 Diabetes Mellitus During Follow-up

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Paliperidone ER vs Olanzapine: Number of Patients Meeting the Criteria for Type 2 Diabetes Mellitus During Follow-up. Trial comparisons, record NCT00645099-95140d01. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00645099-95140d01

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.08790.05820.131wilson
Risk in group 20.1050.07070.152wilson
Risk difference, group 1 minus group 2-0.0167-0.07260.0378newcombe hybrid score
Risk ratio, group 1 over group 20.840.4791.48log
Odds ratio, group 1 over group 20.8250.4431.54log
Number needed to treat, for one fewer participant with the outcome on Paliperidone ER than on Olanzapine60from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Paliperidone ER6-mg or 9-mg tablet once daily flexible dosing for 6 months21239OG000
Group 2Olanzapine10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months23220OG001

Outcome

Type
SECONDARY
Title
Number of Patients Meeting the Criteria for Type 2 Diabetes Mellitus During Follow-up
Description
Fasting plasma glucose ≥126 mg/dL or 2-hour post-load plasma glucose ≥200 mg/dL during an oral glucose tolerance test (OGTT) or initiated use of glucose-lowering agents during the course of the study.
Time frame
6 months
Population
The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement.Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.

Source ClinicalTrials.gov

Trial

Title
A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
NCT number
NCT00645099
Phases
PHASE3
Conditions
Schizophrenia
Interventions
olanzapine, paliperidone ER
Lead sponsor
Janssen-Cilag International NV
Results first posted
2010-07-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00645099-95140d01